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Solid-self-emulsifying drug delivery system (S-SEDDS) of paclitaxel (Ptx) was developed by the spray drying method with the
purpose of improving the low bioavailability (BA) of Ptx. 10% oil (ethyl oleate), 80% surfactant mixture (Tween 80 : Carbitol, 90 : 10,
w/w), and 10% cosolvent (PEG 400) were chosen according to their solubilizing capacity.Themean droplet size, zeta potential, and
encapsulation efficiency of the prepared S-SEDDSwere 16.9± 1.53 nm, 12.5± 1.66mV, and 56.2± 8.1%, respectively. In the S-SEDDS,
Ptx presents in the form of molecular dispersion in the emulsions or is distributed in an amorphous state or crystalline with very
small size. The prepared S-SEDDS formulation showed 70 and 75% dissolution in 60 and 30min in dissolution medium pH 1.2
and 6.8, respectively. Significant increase (𝑃 ≤ 0.05) in the peak concentration (𝐶max), the area under the curve (AUC0–∞), and the
lymphatic targeting efficiency of Ptx was observed after the oral administration of the Ptx-loaded S-SEDDS to rats (20mg/kg as
Ptx). Our research suggests the prepared Ptx-loaded S-SEDDS can be a good candidate for the enhancement of BA and targeting
drug delivery to the lymphatic system of Ptx.
1. Introduction
Paclitaxel (Ptx) is an anticancer drug that has a diterpenoid
pseudoalkaloid structure and is extracted from the bark of
Western yew, Taxus brevifolia [1, 2]. It is active in metastatic
breast cancer and is under evaluation for the adjuvant and
neoadjuvant treatment of early breast cancer [3, 4]. It has been
approved by the US Food and Drug Administration for the
treatment of ovarian and breast cancer, Kaposi’s sarcoma, and
diverse carcinomas including lung, colon, prostate, head and
neck, cervical, and brain [5–7]. Ptx is practically insoluble in
water with a very low aqueous solubility [2, 8, 9]. It is soluble
in a mixture of Cremophor EL and anhydrous ethanol
(50 : 50, v/v) [2, 10]. Thereby, the commercial product of Ptx
(i.e., Taxol, Paxene) is prepared as parenteral formulation
with the mixture of Cremophor EL and ethanol (50 : 50, v/v)
as solvent. The form needs to be diluted with saline to give a
final concentration of 0.03–0.60mg/mL Ptx right before the
injection. However, Cremophor EL has been associated with
serious side effects and leads to hypersensitivity, nephrotoxi-
city, and neurotoxicity in many patients [2, 11].
In the last years, various efforts have been performed
to develop Ptx oral formulation. Oral administration would
offer advantages over intravenous infusion such as being
more attractive for patients because of its simplicity and
would enable the development of chronic treatment sched-
ules resulting in sustained plasma concentrations above a
pharmacologically relevant threshold level. However, orally
administered Ptx presents a major therapeutic problem,
because of low bioavailability (BA) (<10%) [12]. This effect
is mainly due to its low aqueous solubility and dissolution
as well as its affinity for intestinal and liver cytochrome P-
450 metabolic enzymes (i.e., CYP3A4) and the multidrug
efflux transporter P-glycoprotein (P-gp) which is present
abundantly in the gastrointestinal tract [5, 12]. To overcome
this problem, various formulations have been studied and
developed to enhance the oral BA of Ptx, such as liposome [11,
13–15], microsphere [6, 16], nanocapsule [17], nanoparticle
[7, 18–20], nanosponge [12], and combination with P-gp
inhibitors [5, 21, 22].
Self-emulsifying drug delivery system (SEDDS) has got
much attention of researchers in the last decade. The SEDDS
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is an isotropic mixture of oils and surfactants with or
without cosolvents, which spontaneously forms an oil-in-
water nanoemulsion upon gentle agitation with water. Upon
its introduction into aqueousmedia, it forms fine oil-in-water
emulsions with only gentle agitation such as GI motility,
because the free energy required to create a new surface
between the oil and water is lower than the entropy change
that favors dispersion [23]. In comparison to emulsions,
SEDDS can overcome the emulsion system’s shortcoming in
stability, the large volume required, andmanufacturing prob-
lems associated with their commercial production and can
offer an improvement in the rate and extend the absorption by
maximizing the drug solubility within the primer absorption
site of the gut [24]. Moreover, SEDDS can stimulate the
lymphatic transport, because of lipid-based formulation, and
lipid may enhance the extent of lymphatic transport and
increase the BA directly or indirectly by reducing first-pass
metabolism [23, 25–28]. The lymphatic system is a part
of the circulatory system and plays a crucial role in the
immune system’s recognition and response to the disease.
It is the primary route for spreading cancer cells or viruses
and dissemination infections. Once invaded by cancer cells or
viruses, regional lymph nodes act as reservoirs where cancer
cells or viruses take root and seed into other parts of the body
[29–31]. Thus, the lymphatic system is an important target
site for developing new vaccines, anticancer treatments,
immunotherapeutic agents, and imaging agents.The key step
to successfully prepare a SEDDS is finding a suitable oil
phase (oils, surfactants, and/or cosolvents) that has ability to
dissolve the drug at required therapeutic concentration [25].
However, SEDDS has high surfactant concentrations which
in self-emulsifying formulation irritates the GI tract and
volatile cosolvents migrate into the shell of gelatin capsules,
resulting in precipitation of the lipophilic drugs.
Solid-SEDDS (S-SEDDS) has been investigated as an
alternative approach. S-SEDDS combines the advantages
of SEDDS with those of solid dosage forms. A variety of
methods such as adsorptions to solid carriers, spray drying,
melt extrusion, and nanoparticles technology have been
used for the preparation of S-SEDDS [25, 32]. This study
aimed to prepare and characterize the S-SEDDS by the spray
drying method, because of its simplicity [33] in enhancing
drug efficiency and reducing side effects by improving BA
and targeting intestinal lymphatic delivery of Ptx. We also
evaluated the pharmacokinetic characteristics and lymphatic
targeting efficiency of the prepared S-SEDDS in rats.
2. Materials and Methods
2.1. Materials
2.1.1. Reagents. Ptx was kindly supplied by the Korean
Institute of Science and Technology (KIST) (Seoul, Korea).
Glimepiride was kindly supplied by Sam Chun Dang
Pharm. Co., Ltd. (Seoul, Korea). Olive oil, soybean oil,
isopropyl myristate (IPM), oleic acid, polyoxyethylene sor-
bitan monooleate (Tween 80), Cremophor EL, Carbitol,
and dextran were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Ethyl oleate and polyethylene glycol 400 (PEG
400) were purchased from Fischer Scientific (Fair Lawn, NJ,
USA). Propylene glycol was purchased from Junsei Chemical
Co., Ltd. (Tokyo, Japan). Ethylene glycol and ethanol were
purchased from Dae-Jung (Incheon, Korea). Aerosil 200 was
purchased from Evonik Industry. Normal saline solution
(Choongwae Pharma. Co., Seoul, Korea), heparin sodium
(25,000 IU/5mL, Choongwae Pharm. Co., Seoul, Korea),
phosphate buffered saline (PBS, pH 7.4, Sigma-Aldrich, St.
Louis,MO,USA), 70% ethanol, and dichloromethane (DCM,
Dae-Jung, Incheon, Korea) were used for animal experiments
and sample extractions. High-performance liquid chro-
matography (HPLC) grade water obtained from a Milli-Q
water purification system (Millipore Co., Milford, MA, USA)
was used throughout the study except HPLC assay. HPLC
grade acetonitrile and water (Fischer Scientific, Fair Lawn,
NJ, USA) were used for HPLC assay. All other chemicals and
solvents were of analytical grade or highest quality available.
2.1.2. Instruments. Chemical balance (EL204-IC, Mettler-
Toledo, Greifensee, Switzerland), vortex mixer (G560, Scien-
tific Industries Inc., Bohemia, NY, USA), bath-type sonicator
(Kodo Technical Research Co., Ltd., Hwaseong, Korea),
and spray dryer (SD-Basic, Lab-Plant UK Ltd., Filey, North
Yorkshire, UK) were used for preparation of S-SEDDS.
Particle size analyzer (Scatteroscope-I, Qudix, Seoul, Korea),
zeta potential analyzer (ELS-8000, OTSUKA Electronics,
Osaka, Japan), shaking incubator (BS-11, Jeio Tech Co., Ltd.,
Daejeon,Korea), differential scanning calorimeter (DSC823e,
Mettler-Toledo, Greifensee, Switzerland), and X-ray diffrac-
tometer (X’Pert PRO Multipurpose X-Ray Diffractometer,
PANalytical, Almelo, Netherland) were used for the eval-
uation of the prepared S-SEDDS. For animal experiments
the following instruments were used: pH meter (Seve-
nEasy, Mettler-Toledo, Greifensee, Switzerland), homoge-
nizer (IKA-WERKE, KGD-79219, GmbH & Co., Staufen,
Germany), deep-freezer (DF9014, Il-Shin Lab., Seoul, Korea),
centrifugal evaporator (Model CVE-200D, EYELA, Tokyo
Rikakikai Co., Ltd., Tokyo, Japan), centrifuge (Model 5415C,
Brinkmman Instruments Inc., Westbury, NY, USA), Vacu-
tainer (K3 EDTA, 13 × 75mm, Becton Dickinson, Mey-
lan, UK), and polyethylene tube (PE-50, Intramedic, Clay
Adams Co., Parsippany, NJ, USA). HPLC system (Shimadzu
Corp., Kyoto, Japan) consisted of a pump (Model LC-
10ADvp), degasser (model DGU-12A), UV detector (model
SPD-10Avp), system controller (SCL-10Avp), and Shim-Pack
CLC-ODS (M) 15CM column (150 × 4.6mm, 5 𝜇m particle
size).
2.1.3. Experimental Animals. Experimental animals were
managed according to the protocol approved by the Ethical
Review Committee on Experimental Animals of Chonnam
National University, South Korea. Male Sprague-Dawley rats
weighing ∼190–210 g were obtained from Dae Han Biolink
(Eumseong, Korea). Animals were housed separately in a
cage in a ventilated animal roomwith controlled temperature
(19 ± 1∘C) and relative humidity (50 ± 5%), kept on 12 h
light/dark cycle, and provided free access to food (Cheil Food
and Chemical, Incheon, Korea) and water. Rats weighing
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∼240–280 g were used. Prior to the test, the rats were fasted
overnight and had access to water.
2.2. Methods
2.2.1. Preparation of SEDDS
(1) Screening of Oil Phase. Suitable oil, surfactants, and
cosolvents were identified by determining the solubilization
capacities of various oils (olive oil, soybean oil, IPM, ethyl
oleate, and oleic acid), surfactants (Carbitol, Cremophor
EL, Tween 80, Cremophor RH40, and Solutol HS 15), and
cosolvents (PEG 400, ethylene glycol, propylene glycol, and
ethanol) for Ptx, respectively. An excess amount of Ptx was
added to a cap vial containing 500𝜇L of each oil, surfactant,
and cosolvent. After sealing, the mixtures were mixed by
vortexing and heated at 40∘Cusing awater bath and then kept
for 3 days at 37 ± 1∘C in a water shaker to reach equilibrium.
At that time, after centrifuging at 5,000 rpm for 15min to
remove the unsolved Ptx, the supernatants were collected and
recentrifuged. Each supernatant was diluted with a specific
volume of mobile phase and then 20𝜇L was injected into
the HPLC system to determine the solubility of Ptx in each
vehicle [35]. The chosen oil phase was used for further study.
(2) Surfactant Combination Test. Combination study was
conducted to identify the most effective surfactants with
respect to the emulsifying ability of soybean oil, IPM, and
ethyl oleate. Tween 80 and Carbitol were selected for the
combination test based on the results of the screening
of oil phase. As known, each material to be emulsified
requires a surfactant (or a surfactant mixture) with a specific
hydrophilic-lipophilic balance (HLB) number to optimum
emulsification. Use of a surfactant that reaches required HLB
value of the lipid should yield a stable emulsion with a small
and narrow droplet size [36]. The required HLB values of
surfactant (surfactant mixture) for soybean oil, IPM, and
ethyl oleate were reported to be ∼6-7, ∼10–12, and ∼14-15,
respectively [37, 38]. Therefore, we mixed these two surfac-
tants (Tween 80 withHLB of 15 and Carbitol withHLB of 4.2)
at various weight ratios to reach the required range of HLB
value for each of the oils.The optimal oils and corresponding
surfactantmixtures were conducted by visual test and droplet
sizemeasurement of the resulting dispersions.Thepercentage
amount of Tween 80 was calculated by the following equation
[36, 37]:
% Tween 80 =
RHLB −HLBlow
HLBhigh −HLBlow
, (1)
where HLBhigh and HLBlow are the HLB value of Tween
80 (HLB = 15) and that of Carbitol (HLB = 4.2), respec-
tively. RHLB is required HLB value. The weight ratio of
oil : surfactant mixture was fixed at 1 : 9 based on the property
of class III in lipid formulation classification system proposed
by Pouton [39].
(3) Examination of Pseudoternary Phase Diagram. Pseu-
doternary phase diagrams of a mixture containing oil (ethyl
oleate and IPM), surfactant mixtures (Tween 80 : Carbitol) at
different HLB values, and water were constructed using the
water titrationmethod described previously [40, 41]. Briefly, a
predetermined amount of oil-surfactant mixture was diluted
with a specific volume of deionized water (DIW) dropwise.
The ratios of oil-surfactant mixture were varied from 1 : 9
to 9 : 1 at 10% increments. Each mixture was titrated with
water under constant magnetic stirring to reach equilibrium;
then the nature of the resulting emulsions was decided by
turbidity and viscosity with the naked eye [42]. The final oil
and surfactant mixture was determined by comparison of the
emulsion region area in the phase diagrams.
(4) Determination of Optimal Concentration of Cosolvent.
PEG 400was chosen for the test of effect of cosolvent concen-
tration based on the result of evaluation of the solubility test.
The effect of PEG 400 concentration on the droplet size in the
SEDDSwas studied by increasing its concentration from 10 to
40% (w/w). The sort and ratio of oil and surfactant mixture
were selected based on the previous test results.
(5) Determination of Optimal Concentration of Ptx. Ethyl
oleate (10%, w/w), Tween 80 : Carbitol (90 : 10, 80%, w/w),
and PEG 400 (10%, w/w) were fixed to make SEDDS based
on the previous test results. The optimal concentration of
Ptx was determined by measuring the droplet size and drug
encapsulation efficiency (EE). Briefly, 0.5, 1, 2, and 5mg of
Ptx were added to 100mg of blank SEDDS in a cap vial
and then sonicated at 50∘C in a bath-type sonicator until
the Ptx was completely dissolved in the blank SEDDS. Final
formulation was diluted with 100𝜇L of DIW, gently stirred
for 10min, and kept stationary for 2 h at 37 ± 1∘C before
the droplet size and EE measurement. To determine the EE,
the resulting emulsions were centrifuged at 3,000 rpm for
10min to remove undissolved drugs. The supernatants were
collected and added into new glass, followed by diluting with
a specific volume of mobile phase. 20𝜇L of each sample was
injected into the HPLC system for determination. EE was
calculated by the following equation:
EE(%, 𝑤
𝑤
)
=
weight of drug in SEDDS droplets
weight of drug used in preparation of SEDDS
× 100.
(2)
2.2.2. Preparation of S-SEDDS. The S-SEDDS was prepared
by the spray drying method. In detail, the solubilized liquid
SEDDS was atomized into a spray of droplets. The droplets
were introduced into a drying chamber, where the volatile
phase (e.g., the water contained in an emulsion) evaporated,
forming dry particles under controlled temperature and
airflow conditions [32]. To determine the optimal method
for preparation of the S-SEDDS, 100mg of each S-SEDDS
formulation was dispersed into 10mL of DIW by vortexing
and incubated for 6 h at 25∘C [43, 44].The resultant emulsion
was tested for droplet size measurement.This result was basic
of determining the optimal method for preparation of S-
SEDDS.
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Aerosil 200 and dextran were tested to determine the
optimal solid carrier. In the test, Aerosil 200 (500mg) or
dextran (2000mg) was suspended in 100mL of water. After
sonicating at 50∘C in a bath-type sonicator, 1mL of the
optimized liquid SEDDSwas added, followed by stirring con-
stantly until a good suspension was obtained.The suspension
was then spray-dried as previously described to make the S-
SEDDS formulation [31]. In the case of solvent test, water
and ethanol were compared to identify the optimal solvent.
Aerosil 200 (500mg) was suspended in 100mL of solvent and
followed by the described method to prepare the S-SEDDS
formulation. Optimal solid carrier and solvent obtained from
these tests were used for further studies. For determining the
optimal concentration of solid carrier, various amounts of
Aerosil 200 (125, 200, 250, 333, and 500mg) were suspended
in 100mL of water. The S-SEDDS formulation was prepared
as previously described.
2.2.3. Characterization and Evaluation of the Formulation
(1) Measurement of Droplet Size, Zeta Potential, and Drug
Encapsulation Efficiency. The blank liquid SEDDS, blank S-
SEDDS, andPtx-loaded S-SEDDSwere tested for droplet size,
zeta potential, and drug encapsulation efficiency. The mean
droplet size and size distribution of the emulsion droplets
weremeasured by the dynamic light scattering (DLS)method
at room temperature with a 90∘ scattering angle for optimum
detection.The zeta potentials were measured by an ELS-8000
zeta potential analyzer to assess the surface charge and the
stability of the emulsions. For the test, an aliquot of 10 𝜇L
of the liquid SEDDS was diluted with 10mL of DIW in a
cap vial. The samples were gently mixed for 10min and then
kept stationary at 37 ± 1∘C for 1 h. The formulation of the S-
SEDDSwas dispersed inDIW in a volumetric flask to get final
concentration of ∼1.5mg/mL. To ensure complete dispersion
of the formulation, the volumetric flask was inverted twice.
All studies were repeated in five replicates among different
batches and the values of z-average diameters were used. To
determine drug EE, 100 𝜇L of the liquid SEDDS was mixed
with 0.9mL of methanol and vortexed vigorously for 1min.
The solution was then diluted with a specific volume of
mobile phase and injected into the HPLC system for deter-
mination.The blank liquid SEDDS, blank S-SEDDS, and Ptx-
loaded S-SEDDS were reconstituted as previously described.
(2)Thermal Analysis and X-Ray Diffractometry (XRD) Analy-
sis. The endothermic melting temperature for Ptx, blank S-
SEDDS, physical mixture of Ptx/blank S-SEDDS, and Ptx-
loaded S-SEDDS was determined by DSC 2920. The physical
mixture was prepared by mixing well 1.25 g of the blank S-
SEDDS and 10mg of Ptx using mortar and pestle (to make a
similar ratio of Ptx in the physical mixture to that in the Ptx-
loaded S-SEDDS). Samples were scanned from 30 to 280∘C
at a rate of 10∘C/min. In all the cases, an empty pan was
used as the reference. XRD patterns of blank S-SEDDS and
Ptx-loaded S-SEDDS were recorded using an X’Pert PRO
Multipurpose X-Ray Diffractometer equipped with CuK𝛼
radiation (40 kV, 20mA). The 2𝜃 scanning range was varied
from 2 to 100∘.
(3) In Vitro Release Studies. The Ptx-loaded S-SEDDS was
evaluated for in vitro release using the United States Pharma-
copoeia paddlemethod at 37±0.5∘Cat 100 rpm in buffer at pH
1.2 and 6.8. The S-SEDDS was filled in a hard gelatin capsule.
Each sample was placed in a dialysis tube (MWCO: 12,000),
which was placed in a 50mL screw-capped Falcon tube with
10mL of dissolution medium. During the study, 1mL of each
sample was withdrawn at the predetermined time intervals
of 10, 20, 30, 45, and 60min and replaced with fresh buffer.
The samples were centrifuged at 3,000 rpm for 10min, and
the drug concentration was determined by HPLC.
(4) In Vivo Studies. The femoral artery of rats was cannulated
with a PE-50 polyethylene tube under light ether anesthesia.
The cannulated rats were kept in restraining cages under nor-
mal housing conditions for ∼1-2 h until they recovered from
the anesthesia prior to the experiments.The rats were divided
into two groups (five rats per group): (1) Ptx solution diluted
with 1 : 1 blend of Cremophor EL and ethanol (6mg/mL) [22,
45, 46] and (2) Ptx-loaded S-SEDDS. A single dose (20mg/kg
of Ptx) of each formulation was orally administered to rats at
the same time. At the predetermined time intervals (0.5, 1, 1.5,
2, 4, 6, 8, 12, and 24 h), whole blood samples were withdrawn
from the femoral artery into Vacutainer tubes with EDTA.
The blood samples were then centrifuged (3,000 rpm, 10min)
immediately, and plasma was transferred and stored at −80∘C
until assay. Moreover, for the determination of the targeted
lymphatic delivery of Ptx, the rats were also divided into two
groups and given each formulation as mentioned above. At
4 h after the administration, whole blood was taken from
the abdominal aorta, and mesenteric and axillary lymph
nodes were isolated and weighed [47–49]. These lymph node
samples were suspended by homogenization for 1min in PBS
(pH 7.4) to yield a final concentration of 25mg/mL in the
suspension. The samples were stored at −80∘C until assay.
(5) Determination of Ptx in Rat Plasma and Lymph Node
Suspension. The plasma concentration and lymph node sus-
pension of Ptx were determined by HPLC assay following
literature method [50–53] with some modifications. The
chromatographic column used was Shim-Pack column CLC-
ODS (M) 15CM (150 × 4.6mm, 5𝜇m particle size). The
mobile phase consisted of acetonitrile : water (50 : 50, w/w),
and the flow rate was set at 1mL/min. The quantity of Ptx
was measured by the UV absorbance at the wavelength of
227 nm. The stock solutions of Ptx and the internal standard
(I.S., glimepiride) were prepared at 1mg/mL inmethanol and
stored at 4∘C. Calibration standard samples were prepared
by spiking 10 𝜇L aliquot of Ptx working solutions into 90𝜇L
of blank rat plasma or lymph node suspension to give the
final concentrations of Ptx at 10, 20, 50, 100, 200, 500,
and 1000 ng/mL. The calibration curves were obtained by
plotting the peak-area ratio of the analyte to I.S. against
the concentration of Ptx. These samples were treated as
the real rat plasma and lymph node suspension samples.
Liquid-liquid extraction method was used for the extraction
of Ptx from the rat plasma and lymph node suspension
samples. In sum, 100 𝜇L of each sample was placed in an
Eppendorf tube, followed by adding 10 𝜇L of I.S. (glimepiride
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in methanol, 5𝜇g/mL). After vortexing for 30 s, 2mL of
DCM was added and vortexed for 2min for extraction.
After centrifuging at 3,000 rpm for 10min, the upper layer
was aspirated and 1.5mL of the lower organic layer was
transferred to a polypropylene tube and evaporated at room
temperature under vacuum.The residue was reconstituted in
100 𝜇L ofmobile phase, and 20 𝜇Lwas injected into theHPLC
system for determination.
(6) Pharmacokinetic Analysis and Lymphatic Delivery Eval-
uation. The pharmacokinetic parameters such as the area
under the plasma concentration-time curve (AUC
0–∞), time
to peak plasma concentration (𝑇max), and peak concentration
(𝐶max) associatedwith the oral administrationwere estimated
by the noncompartment methods using a WinNonlin
program [54, 55]. Moreover, the targeting efficiency of Ptx to
the lymphatic system was estimated as the ratio of Ptx con-
centration in lymph nodes to the concentration in rat plasma
at 4 h after the oral administration of each formulation [55].
2.2.4. Statistical Evaluation. All the calculated values are
expressed as mean ± SD. All the data were analyzed for
statistical significance by Student’s 𝑡-test with 𝑃 ≤ 0.05
indicating a significant difference.
3. Results and Discussion
3.1. Preparation of SEDDS
3.1.1. Screening of Oil Phase. The oil represents one of the
most important excipients in the SEDDS formulation because
it can solubilize considerable amount of the lipophilic drug
and increase the fraction of the drug transported via the
intestinal lymphatic system. In general, modified medium-
chain triglyceride (MCT) oils, with varying degrees of sat-
uration or hydrolysis, have been used widely for the design
of SEDDS, because the solvent capacity ofMCT for lipophilic
drugs is higher than that of long chain triglyceride (LCT) and
it does not oxidize [24, 56]. Moreover, because the junctions
of the endothelial cells forming walls of lymphatic capillaries
are larger than those of blood capillaries and the rate of
fluid flows in the portal blood is ∼500 times higher than
that of the intestinal lymph [57], the vehicles with small size
enough to penetrate blood capillaries are not easily absorbed
to the lymph. Thereby, fatty acids with long chain length
about 14 or greater, which can produce more hydrophobic
and larger chylomicron in enterocytes, are preferred for
effective lymphatic drug transport than fatty acids having
short carbon chain [58, 59]. Furthermore, the production of
an optimum SEDDS requires relatively high concentrations
(generallymore than 30%w/w) of surfactants to form a stable
SEDDS [60]. The addition of cosolvents aids in enabling
the dissolution of large amounts of hydrophilic surfactants
and also contributes to the improvement of lipophilic drug
solubility in the lipid vehicle [60]. In this study, we screened
various organic solvents, including ethanol, PEG 400, ethy-
lene glycol, and propylene glycol because they are suitable for
oral administration.
Table 1: Solubility of Ptx in various oils, surfactants, and cosolvents.
Solubility# (mg/mL)
Oils
Olive oil 1.00 ± 0.14
Soybean oil 2.29 ± 0.01
IPM (isopropyl myristate) 2.46 ± 0.03
Ethyl oleate 2.88 ± 0.08
Oleic acid 0.38 ± 0.07
Surfactants
Carbitol 70.09 ± 1.02
Cremophor EL 20.13 ± 0.42
Tween 80 52.64 ± 0.77
Cremophor RH40∗ 30.52 ± 1.67
Solutol HS 15∗ 20.74 ± 1.81
Cosolvents
PEG 400 43.28 ± 0.08
Ethylene glycol 9.62 ± 0.25
Propylene glycol 14.35 ± 0.13
Ethanol∗ 32.27 ± 0.29
∗From Sun et al. [34]
#Mean ± SD (𝑛 = 5).
The solubility of Ptx in various oils, surfactants, and
cosolvents is shown in Table 1. Optimal oil and surfactants
are considered as having good solubilization capacity, because
the property of the SEDDS components for dug is important
to achieve the optimum drug loading, prevent precipitation
from SEDDS during the storage and in vivo dilution, and
achieve clear and monophasic formulation at ambient tem-
perature. There were no significant differences among five
chosen oils in terms of the solubility of Ptx, except for olive
oil and oleic acid.
From the result, soybean oil, IPM, and ethyl oleate, Tween
80 (HLB = 15) and Carbitol (HLB = 4.2), and PEG 400
were selected as oil, surfactants, and cosolvent, respectively,
because of the highest solubilization capillary for Ptx.
3.1.2. Surfactant Combination Test. HLB refers to the relative
attraction of a surfactant of emulsifier for water and oil. The
efficiency of self-emulsification is much related to the HLB
of the surfactant [41]. Normally, surfactants with higher HLB
value show a high efficiency on SEDDS [35]. However, low
HLB surfactants may also be an important component of oral
lipid-based formulation by behaving as a coupling agent for
the high HLB surfactants and the lipophilic solvent compo-
nents, as well as contributing to solubilization by remaining
associated with the lipophilic solvent after dispersion. More-
over, using a blend of high and low HLB surfactants may also
lead to more rapid dispersion and finer emulsion droplet size
upon the addition to an aqueous phase [39, 40, 56–58, 61–
63]. Thus, in this study, we mixed a surfactant with high
HLB value (Tween 80 (HLB = 15)) with a surfactant with
low HLB value (Carbitol (HLB = 4.2)) to identify the most
effective combination emulsifying with three chosen oils.The
size of the emulsion droplets decreased as the HLB value of
surfactant mixture reached the required HLB (Table 2). In
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Table 2: The results of droplet size measurement in surfactant combination tests#.
Oil Ratio (%) HLB
Droplet size
(nm)
Tween 80 (HLB = 15) Carbitol (HLB = 4.2) Mean SD
Soybean oil
(required HLB, 6∼7)
15 85 5.8 316 33.9
20 80 6.4 277 2.49
25 75 6.9 473 182
Ethyl oleate
(required HLB, 14∼15)
90 10 13.9 10.5 0.596
95 5 14.5 11.1 0.205
100 0 15 11.5 0.807
IPM
(required HLB, 10∼12)
60 40 10.7 12.9 0.170
65 35 11.2 13.1 0.125
70 30 11.8 13.2 0.974
#The weight ratio of oil : surfactant mixture was fixed at 1 : 9. SD is standard deviation (𝑛 = 5).
Figure 1: The results of visual test in various combination tests.
the case of soybean oil, the smallest size was 277 ± 2.49 nm
obtained at 20 : 80 (w/w) ratio of Tween 80 : Carbitol. In the
cases of ethyl oleate (Tween 80 : Carbitol, 90 : 10, w/w) and
IPM (Tween 80 : Carbitol, 60 : 40), the smallest droplet sizes
were 2.9 ± 0.170 and 10.5 ± 0.596 nm, respectively. These
results show that the combination of Tween 80 and Carbitol
had extremely good emulsifying ability, resulting in a fine
emulsion in the cases of using ethyl oleate and IPM oil.
The results of the visual test (Figure 1) are parallel to the
results of droplet size measurements. The combinations that
had a smaller droplet size of 100 nmor less formed a transpar-
ent or bluish emulsion, and this phenomenon was consistent
with the features of microemulsion in the literature. Overall,
we selected Tween 80 and Carbitol as surfactant mixture for
ethyl oleate and IPM (oil) for further studies.
3.1.3. Examination of Pseudoternary Phase Diagram. Draw-
ing of ternary phase diagrams gives an idea about the com-
position of a selected system and the nature of the resultant
dispersions such as phase separation, coarse emulsions, self-
nanoemulsification and, hence, assists in selecting optimum
formulation [56, 62]. Figure 2(a) shows the phase diagrams
of IPM, water, and surfactant mixtures at the weight ratios of
60 : 40 (HLB = 10.7), 65 : 35 (HLB = 11.2), and 70 : 30 (HLB =
11.8) Tween 80 : Carbitol, respectively. Figure 2(b) shows the
phase diagrams of ethyl oleate, water, and surfactantmixtures
at the weight ratios of 90 : 10 (HLB = 13.9), 95 : 5 (HLB =
14.5), and 100 : 0 (HLB = 15) Tween 80 : Carbitol, respectively.
Filled circles mean self-emulsifying points, and black areas
represent the self-emulsifying regions. In other areas, the
compositions showed inverted emulsion, gel-like form, or
phase separation. In general, when the oil content in the oil
and surfactant mixtures is less than 30%, the condition of the
mixtures changed from water-in-oil emulsion to a clear gel-
like form and then to microemulsion [56]. Otherwise, the
dispersions showed phase separation; this result was similar
to the results previously studied by Guo and Chu [16]. Our
finding showed that IPM + surfactant mixture (65 : 35, w/w)
and ethyl oleate + surfactant mixture (90 : 10, w/w) showed
the most self-emulsifying regions (Figure 2). Overall, in con-
trast to IPM + surfactant mixture (65 : 35, w/w), ethyl oleate
+ surfactant mixture (90 : 10, w/w) showed finer emulsion in
larger self-emulsifying range.These results indicate that ethyl
oleate and Tween 80 : Carbitol (90 : 10, w/w) were identified
as the optimal oil and surfactant mixture, respectively, for
preparing SEDDS.
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Figure 2: Pseudoternary phase diagram with surfactant mixture of Tween 80 : Carbitol. Pseudoternary phase diagram for a mixture of (a)
IPM, water, and surfactant mixture at (a1) 60 : 40 (HLB = 10.7), (a2) 65 : 35 (HLB = 11.2), and (a3) 70 : 30 (HLB = 11.8) weight ratio of Tween
80 : Carbitol and (b) ethyl oleate, water, and surfactant mixture at (b1) 90 : 10 (HLB = 13.9), (b2) 95 : 5 (HLB = 14.5), and (b3) 100 : 0 (HLB =
15) weight ratio of Tween 80 : Carbitol. Filled circles (e) represent studied points, and black areas represent the self-emulsifying regions.
8 Journal of Nanomaterials
Table 3: The results of droplet size measurement in effect of
cosolvent test#.
Cosolvent ratio (%, w/w) Mean (nm) SD (nm)
10 10.7 0.392
20 14.1 0.544
30 17.3 1.537
40 27.5 0.368
#The weight ratio of oil : surfactant mixture was fixed at 1 : 9. SD is standard
deviation (𝑛 = 5).
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Figure 3: Effect of drug incorporation in SEDDS system on
mean droplet size (◼) and encapsulation efficiency (e). Each value
represents the mean ± SD (𝑛 = 5).
3.1.4. Determination of Optimal Concentration of Cosolvent.
As known, cosolvents can be powerful solubilizing agents
for lipophilic molecules. However, it is important to realize
that smaller quantity of cosolvents should be used in SEDDS
because larger amounts can cause drug precipitation on
dispersion into aqueous phase in the in vivo environment on
oral administration [64].
The concentrations of PEG 400 were varied from 10 to
40% (w/w) to evaluate the effect of cosolvent concentration
on the SEDDS droplet size. As shown in Table 3, the mean
droplet size of SEDDS increased with increasing PEG 400
concentration in the range of 11–28 nm. The smallest droplet
size was 10.7 ± 0.392 nm obtained at 10% (w/w) of PEG
400. From these results, the optimal concentration was
determined at 10% (w/w) of PEG 400.
3.1.5. Determination of Optimal Concentration of Ptx. The
mean sizes and EE were used to evaluate the optimal
drug concentration and the effect of drug incorporation on
SEDDS. As shown in Figure 3, the mean droplet size was
maintained in the range of ∼10–15 nm at 0.5, 1, and 2mg
Ptx but dramatically increased to ∼750 nm at the 5mg of
Ptx incorporation on 100mg of SEDDS. Moreover, the EE
decreasedwith increasing drug extent. Itmight be interpreted
that the possibility of precipitation increased with increasing
drug concentration because the calculatedmaximum solubil-
ity of Ptx in this SEDDS (100mg) was about 2mg. Several
Table 4:The results of droplet sizemeasurement in solid carrier and
solvent tests.
Mean (nm) SD (nm)
Solid carrier
Dextran 84.1 1.77
Aerosil 200 29.9 1.15
Solvent
Ethanol 457 29.1
Water 29.9 1.15
Amount of Aerosil 200
500mg 38.03 11.43
333mg 30.67 6.46
250mg 14.37 1.53
200mg 20.73 1.47
SD is standard deviation (𝑛 = 5).
studies observed similar trends: droplet sizes may increase
and EEs may decrease with increasing drug incorporation on
SEDDS [24, 27, 40, 59, 61]. Because there was no significant
difference between 0.5 and 1mg of Ptx incorporation on
SEDDS with respect to droplet size and EE, the optimal drug
concentration was determined at 1mg of Ptx per 100mg of
blank SEDDS.
In summary, the optimal Ptx-loaded liquid SEDDS for-
mulations were prepared as the following procedure: Ptx
(1mg) was added into 100mg of the blank SEDDS that
contains ethyl oleate (oil, 10%, w/w), Tween 80 : Carbitol
(90 : 10, w/w) (surfactant mixture, 80%, w/w), and PEG 400
(cosolvent, 10%, w/w). The resultant mixture was sonicated
at 50∘C in a bath-type sonicator until a clear solution was
obtained (the Ptx was completely dissolved in the blank
SEDDS). This liquid SEDDS formulation containing Ptx was
used for further studies.
3.2. Preparation of S-SEDDS. Aerosil 200 and dextran (solid
carrier) and water and ethanol (solvent) were selected to
determine the optimal solid carrier and solvent for preparing
S-SEDDS. The results of droplet size are shown in Table 4.
There was a significant difference in the size of emulsion
droplets between using Aerosil 200 and dextran as the
solid carrier with the droplet size of 29.9 ± 1.15 nm and
84.1 ± 1.77 nm, respectively. A significant difference was also
observed in the size of emulsion droplet using water and
ethanol as the solvent with droplet size of 29.9 ± 1.15 nm
and 457 ± 29.1 nm, respectively (Table 4). Based on these
results, Aerosil 200 andwater were chosen for further studies.
Table 4 also shows the droplet size of S-SEDDS for the test
determining the optimal amount of solid carrier (Aerosil
200). As shown, the amount of the solid carrier (Aerosil 200)
affects the droplet size of the resultant dispersion.The droplet
size of the S-SEDDS may increase with increasing Aerosil
200 amount over a range of 250 to 500mg. But, the mean
droplet size of S-SEDDSwith 200mgofAerosil 200was larger
than that of S-SEDDS with 250mg of Aerosil 200. And the
formulation preparedwith 125mg ofAerosil 200 did not form
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Figure 4:Themean droplet size (◼) and zeta potential (e) in SEDDS
and S-SEDDS system. Each value represents the mean ± SD (𝑛 = 5).
the S-SEDDS. These phenomena suggested with less than
125mg of Aerosil 200 that the S-SEDDS could not be made
because of the shortage of solid carrier; over a range between
required amount to form solid formulation and 250mg of
Aerosil 200, the droplet size of the S-SEDDSmay not increase
with increasing Aerosil 200 amount; but with more than
250mg of Aerosil 200, there was a trend that the droplet size
increases with increasing Aerosil 200. Based on these results,
an amount of 250mg of Aerosil 200 was chosen for preparing
optimal S-SEDDS.
In summary, the optimal S-SEDDS was prepared as
follows: Aerosil 200 (250mg) was suspended in 100mL of
water. After sonicating at 50∘C in a bath-type sonicator, 1mL
of the optimized liquid SEDDS was added and followed by
stirring constantly until a good suspension was obtained.The
suspension was then spray-dried as previously described.
3.3. Characterization and Evaluation of the Formulation
3.3.1. Measurement of Droplet Size, Zeta Potential, and Drug
Encapsulation Efficiency. The mean droplet size and zeta
potential of Ptx-loaded S-SEDDS were not significantly
different from those of the blank liquid SEDDS droplet and
blank S-SEDDS (Figure 4). In detail, the mean sizes of liquid
SEDDS, blank S-SEDDS, and Ptx-loaded S-SEDDS droplets
in DIW were 15.6 ± 0.395, 16.9 ± 1.53, and 18.4 ± 0.912 nm,
respectively. The zeta potential of liquid SEDDS, blank S-
SEDDS, and Ptx-loaded S-SEDDS droplets inDIWwas 11.1±
0.965, 11.4 ± 0.587, and 12.5 ± 1.66mV, respectively. From
these results, we expected that the prepared Ptx-loaded S-
SEDDS can be a good candidate to improve the BA and
biocompatibility by targeting Ptx to the lymphatic system.
3.3.2. Thermal Analysis and X-Ray Diffractometry (XRD)
Analyses. Thephysical status of Ptx in the prepared S-SEDDS
was investigated since it would have an important influence
on the in vitro and in vivo release characteristics. The DSC
thermograms for Ptx, the blank S-SEDDS, physical mixture
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Figure 5: DSC thermograms of (A) Ptx, (B) blank S-SEDDS, (C)
physical mixture of Ptx/blank S-SEDDS, and (D) Ptx-loaded S-
SEDDS.
of Ptx/blank S-SEDDS, and Ptx-loaded S-SEDDS are shown
in Figure 5 (the DSC thermograms). Pure Ptx showed a sharp
endothermic peak corresponding to a melting point of ∼
220∘C (curve (A)). This value was consistent with reported
melting point of Ptx in previous literature [65–67]. A similar
endothermic peak for Ptx was observed in the physical
mixture of Ptx/blank S-SEDDS (curve (C)). In contrast, such
peaks were not found in the blank S-SEDDS (curve (B)) and
in the Ptx-loaded S-SEDDS (curve (D)).The results indicated
that the drug would be either molecularly dispersed in the S-
SEDDS formulation or distributed in an amorphous state or
crystalline with very small size.
This suggestion was also confirmed by the XRD study. As
known, the intensity of the XRD peak depends on the crystal
size. Ptx powder exhibited several intense diffraction peaks
[68]. However, these peaks were not observed in the XRD
patterns of blank S-SEDDS (Figure 6(a)) and Ptx-loaded S-
SEDDS (Figure 6(b)).
3.3.3. In Vitro Release Studies. As mentioned above, in the
SEDDS, the free energy required to create a new surface
between the oil and water is very low. It is suggested that the
oil/surfactant/cosolvent and water phases effectively swell,
decrease the droplet size, and eventually increase the release
rate. In vitro dissolution profiles of Ptx in pH 1.2 and 6.8
from the Ptx-loaded S-SEDDS are displayed in Figure 7.
The release ratios of Ptx from the Ptx-loaded S-SEDDS in
pH 1.2 and 6.8 reached 70 and 75% within 60 and 30min,
respectively. Aerosil 200 is hydrophilic fumed silica and is
dispersed easily in both the two buffers. Thereby, it seems to
have no effect on the release rate of Ptx from the formulation.
Additionally, because Ptx is a weak base (pKa = 10.36), its
solubility increaseswith decreasing the pH; a higher solubility
can be obtained in pH 1.2 buffer than in pH 6.8 buffer. But, as
shown in Figure 7, the release rate of Ptx in pH 6.8 buffer was
higher and faster than that in pH 1.2 buffer, especially within
the first 30min. This inverse phenomenon may be attributed
to the effect of environmental pH on the hard gelatin capsule
and the dialysismembrane for a short period of time (30min)
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Figure 6: XRD patterns of (a) blank S-SEDDS and (b) Ptx-loaded S-SEDDS.
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Figure 7: In vitro dissolution profiles of Ptx from the S-SEDDS in
pH 6.8 and 1.2 at 37 ± 0.5∘C. Each value represents the mean ± SD
(𝑛 = 5).
which indirectly affects the release rate of Ptx from the S-
SEDDS formulation.
More importantly, according to the previous report on
dissolution profiles of Ptx powder, it took 72 h to release 3.2%
of Ptx in pH 6.8 buffer [14]. In comparison to the report, a
dramatic increase in dissolution of Ptx was observed in the
Ptx-loaded S-SEDDS. This effect may be due to the small
droplet size of the formulation resulting in a higher surface
area of drug exposed to the dissolution media which permits
a faster rate of drug release into aqueous phase. Additionally,
the effect was attributed to the improvement of drug disso-
lution by the surfactant mixture (Tween 80 : Carbitol) and
Aerosil 200. The study ensured that the S-SEDDS preserved
the improvement of in vitro dissolution of liquid SEDDS.
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Figure 8: Rat plasma concentration-time profiles of Ptx after oral
administration (20mg/kg) of the Ptx-loaded S-SEDDS and Ptx
solution to rats. Each value represents the mean ± SD (𝑛 = 5).
3.3.4. Pharmacokinetic Analysis and Lymphatic Delivery Eval-
uation. Figure 8 shows the mean rat plasma concentration-
time profiles of Ptx after the oral administration of Ptx-
loaded S-SEDDS and reference solution (20mg/kg as Ptx,
Cremophor EL : ethanol = 1 : 1), respectively. Table 5 lists the
pharmacokinetic parameters obtained by the noncompart-
mental methods using WinNonlin. After the oral admin-
istration, the pharmacokinetic parameters related with BA
such as AUC
0–∞ and 𝐶max of the Ptx-loaded S-SEDDS
(3308.5±486.2 ng⋅hr/mL and 259.5±7.5 ng/mL, resp.) showed
significant differences (𝑃 ≤ 0.05) in comparison to those of
the reference solution (1816.5 ± 206.4 ng⋅h/mL and 84.6 ±
4.1 ng/mL, resp.). AUC
0–∞ and 𝐶max of the Ptx-loaded S-
SEDDS were 1.8 and 3.0 times higher than those of the ref-
erence solution. The concentrations of Ptx in the mesenteric
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Figure 9: (a) Concentration of Ptx in mesenteric and axillary lymph nodes at 4 h after the oral administration of Ptx solution and Ptx-
loaded S-SEDDS to rats. (b) Lymphatic targeting efficiencies of Ptx in mesenteric and axillary lymph nodes at 4 h after oral administration
(20mg/kg) of the Ptx-loaded S-SEDDS and Ptx solution to rats. Vertical bar represents the mean ± SD (𝑛 = 5). ∗𝑃 ≤ 0.05 between the
S-SEDDS formulation and paclitaxel solution.
Table 5: Pharmacokinetic parameters of Ptx after the oral adminis-
tration (20mg/kg) of the Ptx reference and Ptx-loaded S-SEDDS in
rats (𝑛 = 5).
Parameters Oral administrationPtx solution S-SEDDS
𝐶max (ng/mL)
# 84.6 ± 4.1 259.5 ± 7.5
𝑇max (hr) 1.8 ± 0.2 1.7 ± 0.2
AUC
0–∞ (ng⋅hr/mL)
# 1816.5 ± 206.4 3308.5 ± 486.2
#
𝑃 ≤ 0.05.
and axillary lymph nodes after the oral administration are
shown in Figure 9(a), in which the concentrations of Ptx after
the administration of Ptx-loaded S-SEDDS were significantly
higher than those of the reference solution in both lymph
nodes. Moreover, the lymphatic targeting efficiencies of Ptx
calculated as the ratio of the lymph node concentration to
the plasma concentration are shown in Figure 9(b). The Ptx-
loaded S-SEDDS shows higher lymphatic targeting efficien-
cies than those of the reference solution. In the mesenteric
lymph nodes, there was a significant difference (𝑃 ≤ 0.05)
between the Ptx-loaded S-SEDDS and reference solution.
This increased lymphatic targeting efficiency can lower the
drug amount required to have a clinical effect. Moreover,
because of increasing efficiency at the targeted sides, the use
of Ptx might reduce the systemic side effects. These results
suggest that the prepared S-SEDDS containing Ptx could be
used as effective oral formulation for enhancing the BA of Ptx
and targeting drug delivery to the lymphatic system.
4. Conclusions
We have prepared S-SEDDS containing Ptx easily and repro-
ducibly by the spray drying method for enhancing the
BA and targeted delivery of Ptx to the lymphatic system.
The Ptx-loaded S-SEDDS was prepared using Aerosil 200
(250mg), water (100mL), and Ptx-loaded liquid SEDDS
(1mL).The Ptx-loaded liquid SEDDS consisting of Ptx (1mg)
and blank liquid SEDDS (100mg) which contains 10% oil
(ethyl oleate), 80% surfactant mixture (Tween 80 : Carbitol,
90 : 10, w/w), and 10% cosolvent (PEG 400) is an optimal
formulation in terms of mean emulsion droplet size, zeta
potential, and encapsulation efficiency. The optimal Ptx-
loaded S-SEDDS formulation showed 16.9±1.53 nm, 12.47±
1.66mV, and 56.2 ± 8.1% in mean emulsion droplet size,
zeta potential, and encapsulation efficiency, respectively.
Both DSC measurements and X-ray diffraction analysis
suggested that Ptx in the S-SEDDS may be in the form
of molecular dispersion in the emulsions or distributed in
an amorphous state or crystalline with very small size. In
vitro dissolution test showed that the prepared S-SEDDS
had a dramatic increase in in vitro release rate than the
powder. Furthermore, from the in vivo studies, the prepared
Ptx-loaded S-SEDDS showed significant increases (𝑃 ≤
0.05) in AUC
0–∞, 𝐶max, and lymphatic targeting efficiency
in comparison to those of the reference solution after the
oral administration. In conclusion, our research suggested
that the prepared S-SEDDS formulation could be a good
candidate for the enhancement of BA and delivery of Ptx to
the lymphatic system, and this approach also could be used
as an alternative formulation technology for other low BA
drugs.
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